BioSpace News Archive

Business

Verily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases

Verily and Kyverna Therapeutics (“Kyverna”) today announced a multi-year collaboration to identify novel biomarkers and innovate clinical trial design and execution.

September 7, 2023

·

5 min read

Biotech Beach

Viking Therapeutics to Participate at Upcoming Investor Conferences - September 7, 2023

Viking Therapeutics, Inc. today announced that the company will participate at two upcoming investor conferences.

September 7, 2023

·

3 min read

Genetown

Azenta to Participate in the Baird 2023 Global Healthcare Conference

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Baird 2023 Global Healthcare Conference in New York, NY, on Tuesday, September 12, 2023, which includes a presentation beginning at 9:05 am ET.

September 7, 2023

·

1 min read

Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases

September 7, 2023

·

7 min read

Genetown

Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report – “Nasopharyngeal Carcinoma: Global Clinical Trial Landscape”.

September 7, 2023

·

2 min read

Verisante Technology Inc. Announces Shares for Debt Agreements

Verisante Technology, Inc. is pleased to announce it has agreed to convert certain payables owed to Creditors into common shares in the capital of the Company.

September 7, 2023

·

2 min read

BioForest

Gilead Prices $2 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053.

September 7, 2023

·

3 min read

Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.

September 7, 2023

·

1 min read

BioMidwest

Lynch Regenerative Medicine, Inc. Launched to Revolutionize the Skincare Market

Dr. Samuel Lynch, DMD and DMSc, a serial biotechnology entrepreneur, has announced the launch of Lynch Regenerative Medicine, Inc., a new advanced biotherapeutics skincare company targeting unmet clinical needs in both the aesthetic and advanced wound care markets.

September 7, 2023

·

3 min read

Deals

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals, Inc. announced that leading independent proxy advisor Institutional Shareholder Services Inc. has recommended that stockholders vote FOR the Company’s previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.

September 7, 2023

·

9 min read